Hepatitis B, a global public health problem, plagues many patients. In the long-term treatment of hepatitis B, the problem of drug resistance has become an urgent challenge, as is the “fells” of ships in flight, threatening the smooth running of treatment and the health of patients.
The incidence of hepatitis B resistance is mainly related to the characteristics of the hepatitis B virus and the mechanism for the functioning of antivirals. Hepatitis B has a high degree of variability and, under the pressure of drug choice, the virus can undergo genetic mutation, thus creating resistance to drugs. Hepatitis B antiviral drugs, such as nucleotide (acid) analogues, are commonly used to control the condition by inhibiting the reproduction of hepatitis B virus. However, in the long-term use of these drugs, the Hepatitis B virus in some patients is likely to mutate, making it impossible for otherwise effective drugs to contain the virus as effectively as before, leading to its re-emergence and recurrence.
Hepatitis B resistance does not occur overnight, but is an evolving process. At the initial stage of treatment, the risk of drug resistance mutation of the virus can be significantly increased if the patient does not regulate the use of drugs, such as self-detoxification, leakage or reduction of the dose. In addition, some patients themselves may experience some genetic mutations associated with resistance, which also creates an ambush for subsequent resistance problems.
Hepatitis B resistance may not be apparent in the early stages of clinical symptoms, but as the condition evolves, the patient may experience anomalous liver function, e.g. increased aminoase, chlamydia, etc. Some patients may also experience symptoms of discomfort, appetite, nausea, vomiting, abdominal swelling and liver pain, similar to those of increased hepatitis B. If hepatitis B is not detected and treated in a timely manner, hepatitis B resistance is likely to lead to sustained progress in hepatitis and even to serious complications, such as hepatic cirrhosis and liver cancer, which have a serious impact on the quality of life and the prognosis of patients.
For the diagnosis of hepatitis B resistance, doctors need to integrate information on multiple aspects. First, patients are asked in detail about their drug history, including the type of antiviral drugs used, the dose used, the time spent on the drug, and whether there are any irregularities. Second, patients are regularly screened for serophysics, and changes in indicators such as Hepatitis B virus DNA Quantification, Hepatitis B five indicators, liver function, etc. If, in the course of treatment, hepatitis B virus DNA levels are found to rise again after reaching a certain level of inhibition, or if the previously declining amino enzyme is raised again, and other factors that may cause fluctuations in the condition, such as alcohol consumption and the combination of other hepatitis virus infections, etc., require a high level of vigilance about the possibility of hepatitis B resistance. Further examinations may also include genetic resistance tests for Hepatitis B virus to determine, by testing the genetic sequence of the virus, whether there is a genetic mutation associated with the drug resistance, in order to identify the type and location of the drug resistance, and to provide a precise basis for subsequent programme adjustments.
The timely adjustment of treatment programmes is essential once hepatitis B is diagnosed as resistant. Depending on the results of the drug resistance test, the doctor selects the appropriate cure for the patient ‘ s condition. Currently, there are a number of options available for different types of hepatitis B resistance, such as the substitution of other antiviral drugs without cross-resistant drugs or the joint use of drugs with different mechanisms. At the same time, patients must comply strictly with medical prescriptions in the course of their treatment, take their medication on time and on a scale, and avoid re-emergence of irregularities, in order to improve the success of the treatment and control the development of the condition.
The prevention of hepatitis B resistance is a key component of hepatitis B treatment. First, in the initial treatment, doctors consider the selection of appropriate antivirals, taking into account the patient ‘ s condition, age, physical condition and financial condition, with a view to reducing the risk of resistance while ensuring the effectiveness of the treatment. In the case of patients, it is of the utmost importance to strictly regulate the use of medicines in accordance with the instructions of the doctor, and it is essential not to stop, change or reduce the amount of medicines. Regular reviews are conducted at the hospital to keep abreast of changes in the condition and the effects of the treatment, so that doctors can adapt their treatment to the actual situation. In addition, maintaining a healthy lifestyle, such as a reasonable diet, a proper amount of exercise, absortment from smoking and alcohol, and the avoidance of overwork, also helps to increase the body ‘ s immunity and its ability to combat the virus, thereby reducing to some extent the incidence of hepatitis B resistance.
Although hepatitis B resistance is a serious challenge in the treatment of hepatitis B, as long as patients and doctors work together to raise awareness of the problem, take effective preventive measures and detect and deal with it in a timely manner, it will be possible to bypass the “cathals” on the path to hepatitis B treatment and move steadily towards the goal of curing hepatitis B so that the patient can embrace a healthy life again.
Hepatitis B
